CCNG2 expression based on
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Comparison | Statistical significance |
Normal-vs-Primary | 1.40720768371239E-12 |
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Stage1 |
1.00499999999837E-06 |
Normal-vs-Stage2 |
2.986400E-04 |
Normal-vs-Stage3 |
N/A |
Normal-vs-Stage4 |
3.960000E-03 |
Stage1-vs-Stage2 |
1.503850E-01 |
Stage1-vs-Stage3 |
N/A |
Stage1-vs-Stage4 |
5.653000E-01 |
Stage2-vs-Stage3 |
N/A |
Stage2-vs-Stage4 |
5.278200E-01 |
Stage3-vs-Stage4 |
N/A |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Caucasian |
9.93060078613439E-11 |
Normal-vs-AfricanAmerican |
2.241000E-01 |
Normal-vs-Asian |
2.091900E-02 |
Caucasian-vs-AfricanAmerican |
6.669900E-02 |
Caucasian-vs-Asian |
1.365170E-01 |
AfricanAmerican-vs-Asian |
6.360000E-01 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Male |
4.93599999995542E-06 |
Normal-vs-Female |
7.98320000106045E-08 |
Male-vs-Female |
3.874000E-01 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Patient BMI information is not available for 1 sample.
Descriptions |
Normal weight |
BMI greater than equal to 18.5 and BMI less than 25 |
Extereme weight |
BMI greater than equal to 25 and BMI less than 30 |
Obese |
BMI greater than equal to 30 and BMI less than 40 |
Extreme Obese |
BMI greater than 40 |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Normal_Weight |
1.944070E-03 |
Normal-vs-Extreme_Weight |
2.21400000000038E-05 |
Normal-vs-Obese |
4.370000E-04 |
Normal-vs-Extreme_Obese |
N/A |
Normal_Weight-vs-Extreme_Weight |
8.209800E-01 |
Normal_Weight-vs-Obese |
2.794000E-01 |
Normal_Weight-vs-Extreme_Obese |
N/A |
Extreme_Weight-vs-Obese |
3.470200E-01 |
Extreme_Weight-vs-Extreme_Obese |
N/A |
Obese-vs-Extreme_Obese |
N/A |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Age(21-40Yrs) |
2.457800E-01 |
Normal-vs-Age(41-60Yrs) |
1.340310E-03 |
Normal-vs-Age(61-80Yrs) |
1.71320002628761E-09 |
Normal-vs-Age(81-100Yrs) |
4.586000E-01 |
Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.559200E-01 |
Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.800800E-01 |
Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.382800E-01 |
Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.147830E-01 |
Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.748800E-01 |
Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.753800E-01 |
|
|
CHOL : Cholangiocarcinoma
Subtype descriptions |
Grade 1 | Well differentiated (low grade) |
Grade 2 | Moderately differentiated (intermediate grade) |
Grade 3 | Poorly differentiated (high grade) |
Grade 4 | Undifferentiated (high grade) |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Grade 1 |
N/A |
Normal-vs-Grade 2 |
2.249800E-01 |
Normal-vs-Grade 3 |
3.209400E-01 |
Normal-vs-Grade 4 |
1.000000E+00 |
Grade 1-vs-Grade 2 |
N/A |
Grade 1-vs-Grade 3 |
N/A |
Grade 1-vs-Grade 4 |
N/A |
Grade 2-vs-Grade 3 |
8.119000E-01 |
Grade 2-vs-Grade 4 |
2.249800E-01 |
Grade 3-vs-Grade 4 |
3.209400E-01 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 5 samples.
pathologic_N descriptions |
N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-N0 |
1.48440000291572E-08 |
Normal-vs-N1 |
3.399500E-03 |
N0-vs-N1 |
2.837400E-01 |
|
|